Impact of low-dose prasugrel on platelet reactivity and cardiac dysfunction in acute coronary syndrome patients requiring primary drug-eluting stent implantation: A randomized comparative study
Catheterization and Cardiovascular Interventions Apr 19, 2019
Kitano D, et al. - Researchers compared prasugrel and clopidogrel with respect to their impacts on platelet aggregation reactivity, cardiac enzyme release, cardiac remodeling, and the formation of in-stent thrombi post- primary percutaneous coronary intervention (PCI). Random assignment of 78 acute coronary syndrome (ACS) patients to clopidogrel (300 mg loading/75 mg maintenance) or prasugrel (20 mg loading/3.75 mg maintenance) was done, after which primary PCI was performed. A stable platelet aggregation inhibitory effect of prasugrel was evident, regardless of CYP2C19 genotype, as well as it attenuated cardiac enzyme release, and prevented cardiac remodeling post-ACS, when compared to clopidogrel.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries